Resveratrol improves diabetic kidney disease by modulating the gut microbiota-short chain fatty acids axis in db/db mice

Int J Food Sci Nutr. 2024 May;75(3):264-276. doi: 10.1080/09637486.2024.2303041. Epub 2024 Jan 18.

Abstract

Diabetic kidney disease is associated with the dysbiosis of the gut microbiota and its metabolites. db/db mice were fed chow diet with or without 0.4% resveratrol for 12 weeks, after which the gut microbiota, faecal short-chain fatty acids (SCFAs), and renal fibrosis were analysed. Resveratrol ameliorated the progression of diabetic kidney disease and alleviated tubulointerstitial fibrosis. Further studies showed that gut microbiota dysbiosis was modulated by resveratrol, characterised by the expansion of SCFAs-producing bacteria Faecalibaculum and Lactobacillus, which increased the concentrations of SCFAs (especially acetic acid) in the faeces. Moreover, microbiota transplantation experiments found that alteration of the gut microbiota contributed to the prevention of diabetic kidney disease. Acetate treatment ameliorated proteinuria, glomerulosclerosis and tubulointerstitial fibrosis in db/db mice. Overall, resveratrol improved the progression of diabetic kidney disease by suppressing tubulointerstitial fibrosis, which may be involved, at least in part, in the regulation of the gut microbiota-SCFAs axis.

Keywords: Resveratrol; diabetic kidney disease; gut microbiota; short-chain fatty acids.

MeSH terms

  • Animals
  • Diabetic Nephropathies* / drug therapy
  • Dysbiosis
  • Fatty Acids, Volatile* / metabolism
  • Feces / microbiology
  • Fibrosis
  • Gastrointestinal Microbiome* / drug effects
  • Kidney / drug effects
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Resveratrol* / pharmacology

Substances

  • Fatty Acids, Volatile
  • Resveratrol